
TNDM Stock Forecast & Price Target
TNDM Analyst Ratings
Bulls say
Tandem Diabetes Care has shown a robust financial trajectory, with a notable 10–11% year-over-year growth anticipated in US pump shipments, driven by a strong renewal pump segment and a positive outlook on new patient starts. The management's emphasis on improving pharmacy access indicates a broader market expansion, facilitating more affordable options for new patients and enhancing overall sales channels. Additionally, revenue projections for 2026 and 2027 reflect slight increases, reinforcing a positive outlook on continued growth momentum in the durable insulin pump market.
Bears say
Tandem Diabetes Care's revenue forecast for 2026 has decreased slightly to $1.07 billion, with EBITDA projected to be negative, highlighting financial strain. The guidance for US revenue anticipates a headwind of approximately $70–$80 million from Pay-Go pump shipments, and there is a projected decline of 3% in new patient starts. Additionally, there are significant risks, including increased competitive pressures, challenges in securing profitable pharmacy channel contracts, and the uncertain profitability of the newly launched Mobi pump, all of which could adversely impact the company’s financial outlook.
This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.
TNDM Analyst Forecast & Price Prediction
Start investing in TNDM
Order type
Buy in
Order amount
Est. shares
0 shares